ALFA FinderBSE filing, NSE: ORCHPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.
Orchid Pharma Annual General Meeting
Orchid Pharma held its 33rd Annual General Meeting on September 29, 2026, where shareholders considered and approved routine business resolutions and related party transactions.
Other board meeting date announcements
All →Mitshi India Board Meeting Date
Mitshi India rescheduled its board meeting from 13 Nov to 14 Nov 2026 due to non-availability of directors. The meeting's agenda includes Q2/H1 2026 financial results approval.
Magnus Steel and Infra Board Meeting Date
Magnus Steel and Infra has scheduled its board for 14 Nov 2026 to approve standalone results for the quarter and half year ended 30 Sep 2026. The trading window is closed from 1 Oct 2026.
Ansal Properties & Infrastructure Board Meeting Date
Ansal Properties & Infrastructure intimated that its Board will meet on 18 Nov 2026 to approve Q1 FY27 standalone results. The meeting is scheduled and has not yet been held.
Boston Commerce Board Meeting Date
Boston Commerce Ltd scheduled its board meeting for 15 Nov 2026 to consider unaudited results for Q2 and Q1/H1 FY27. The trading window will remain closed until 48 hours after results declaration.
Associated Ceramics Board Meeting Date
Associated Ceramics has scheduled a board meeting on November 14, 2026 to consider unaudited standalone September 2026 half-yearly results. Advance notice; meeting not yet held.
Dudani Retail Board Meeting Date
Dudani Retail has given intimation of a board meeting on 14 November 2026 to consider unaudited half-year standalone results and related statements. The trading window stays closed until 48 hours after the results are declared.